September 10, 2018 Interview with Dr. Frank Mathias, CEO, Dr. Ralf Otto, COO, and Federico Pollano, SVP Business Development, in European Business Magazine

From gene to vial and from clinic to market

The independent family-owned company Rentschler Biopharma SE is proud of its incredible 90 year history and track record in the production of pharmaceuticals. Today, the company is among the five largest contract development and manufacturing organizations (CDMO). In their interview with European Business Magazine, Dr. Frank Mathias, Dr. Ralf Otto and Federico Pollano share Rentschler Biopharma's secret of success as a CDMO.

Rentschler Biopharma offers end-to-end services, covering the whole biopharmaceutical value chain from gene to vial and from clinic to market. "Rentschler Biopharma is one of the very few firms to genuinely focus on developing and manufacturing biopharmaceuticals exclusively for customers," stressed Federico Pollano. Moreover, the company closely collaborates with its customers, who are considered as partners.

With more than 250 projects successfully completed worldwide, Rentschler Biopharma provides significant experience. Dr. Ralf Otto is proud of Rentschler Biopharma's highly motivated employees: "Our dedicated staff do not fear complexity and continue working where others would perhaps give up."

Rentschler Biopharma is also addressing recent market developments. "We grow with our customers. Because we offer tailored solutions, up to 3,000 l bioreactors, we are well positioned to cover the area of rare diseases, where focused batches are needed," explains Dr. Frank Mathias. Federico Pollano adds, "Personalized medicine is the current market trend. In this segment, we are incredibly innovative."

For further insights, please have a look at our complete article here.